Project Grant K08HL173569
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $713,421 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 3, 2025, with completion targeted for June 30, 2029. This research initiative investigates the regulation of thin filament architecture by Cyclase-Associated Protein 2 (CAP2) in cardiac health and myopathy, with the objective of elucidating mechanisms...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Vermont & State Agricultural College a $713,511 Project Grant on August 18, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms by which mutations in the MYBPC3 gene lead to hypertrophic cardiomyopathy (HCM). The research examines how reduced levels of myosin-binding protein C (MyBP-C) disrupts myosin function and thick filament...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $511,987 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 27, 2025, with a completion date of May 31, 2029. This award funds a comparative research study investigating the molecular mechanisms of lamin A/C (LMNA)-related dilated cardiomyopathy, a severe form of adult-onset heart disease. The...
- This $488,575 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research to understand how myosin binding protein-C (MYBP-C) regulates skeletal muscle contraction and how mutations in the genes encoding slow and fast MYBP-C cause congenital skeletal muscle diseases. The research aims to systematically determine the distinct functional and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Wright State University a Project Grant totaling $165,456 on August 14, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This five-year award funds an integrated research and career development program focused on neuromuscular junction dysfunction in hyperkalemic periodic paralysis (HPP), a rare genetic disorder caused by mutations affecting muscle sodium...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $229,152 Project Grant awarded on July 27, 2025, by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative, scheduled for completion by March 31, 2028, focuses on investigating the structure, function, and drug treatment of the native cardiac sarcomere in hypertrophic cardiomyopathy (HCM), the most common genetic...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Trustees of Columbia University in the City of New York a $3.06 million Project Grant effective September 1, 2025, through August 31, 2028, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project investigates the molecular mechanisms of excitation-contraction coupling (ECC) dysfunction in skeletal muscle weakness...
- Federal Grant Award Summary Boston Children's Hospital received a $171,488 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded January 22, 2026, with completion targeted for August 31, 2028. The research project investigates CMYA5 (Cardiomyopathy-Associated Protein 5) as a novel endogenous regulator of Ryanodine Receptor 2 (RYR2) channel activity in cardiomyocytes. The study addresses mechanisms...
- This project grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) totals $683,016 and was awarded on May 8, 2026, with an ultimate completion date of April 30, 2031. Brigham and Women's Hospital Inc., operating through the Department of Faulkner Pathology in Boston, Massachusetts, serves as the prime awardee for this research initiative. The project delivers...
- The CHERISH (Duchenne Cardiomyopathy Mitigation SGLT2 Inhibitor) project, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), received $889,676 in federal funding with an award date of September 4, 2025, and completion date of August 31, 2027. Led by Indiana University Indianapolis, this clinical research initiative evaluates the use of sodium/glucose cotransporter-2 inhibitors (SGLT2i) as a therapeutic intervention...
MULTI-SCALE ANALYSIS OF THE ROLE OF SKELETAL MUSCLE ACTIN MUTATIONS IN DILATED CARDIOMYOPATHY - PROJECT ABSTRACT THERE ARE TWO MAIN OBJECTIVES FOR THIS 5-YEAR CAREER DEVELOPMENT PLAN: 1) DEFINE THE ROLE AND MECHANISTIC BASIS OF SKELETAL MUSCLE ACTIN MUTATIONS IN DILATED CARDIOMYOPATHY (DCM), AND 2) TRANSITION THE PRINCIPAL INVESTIGATOR (PI) TO INDEPENDENCE THROUGH PROFESSIONAL AND SCIENTIFIC MENTORSHIP. DESPITE CURRENT THERAPIES, MANY PATIENTS WITH DCM PROGRESS TO END STAGE HEART FAILURE POSSIBLY DUE TO A LACK OF TREATING CHANGES IN CONTRACTILITY WHICH NEEDS FURTHER EXPLORATION. THE BASIS OF ALL CONTRACTION IN CARDIAC AND SKELETAL MUSCLES IS MYOSIN PULLING ON ACTIN FILAMENTS. SKELETAL MUSCLE ACTIN IS THE MINOR ACTIN ISOFORM IN THE HEART, AND IT HAS NEVER BEEN MECHANISTICALLY EXPLORED IN DCM. IN THIS PROPOSAL, THE PI ESTABLISHES A MULTISCALE EXPERIMENTAL PLATFORM THAT UTILIZES BIOCHEMICAL, BIOPHYSICAL, AND IN VIVO METHODS TO ROBUSTLY STUDY THE EFFECTS OF THE SKELETAL MUSCLE ACTIN MUTATION R256H ON HEART AND SKELETAL MUSCLE. THE PI PREVIOUSLY FOUND THAT R256H EXCEPTIONALLY ASSOCIATES WITH DCM WITHOUT SKELETAL MYOPATHY UNLIKE ALL OTHER SKELETAL MUSCLE ACTIN MUTATIONS. HIS PRELIMINARY DATA DEMONSTRATES THAT R256H HAS A DOMINANT NEGATIVE EFFECT ON CONTRACTILITY ONLY IN THE PRESENCE OF THE ACTIN-BINDING PROTEINS TROPONIN AND TROPOMYOSIN WHICH IS A NOVEL MECHANISM THAT WAS DISCOVERED USING A NEW TECHNIQUE OF RECOMBINANT ACTIN PURIFICATION CREATED BY THE PI. HE ALSO ESTABLISHES THAT R256H CAUSES HYPCONTRACTILITY IN HUMAN CARDIOMYOCYTES AND MOUSE HEARTS. HE HYPOTHESIZES THAT R256H CAUSES DCM WITHOUT SKELETAL MYOPATHY DUE TO TISSUE-SPECIFIC EXPRESSION OF DIFFERENT ISOFORMS OF TROPONIN AND TROPOMYOSIN. THIS HYPOTHESIS WILL BE TESTED BY ELUCIDATING THE BIOCHEMICAL AND STRUCTURAL EFFECTS OF R256H IN THE CONTEXT OF CARDIAC AND SKELETAL MUSCLE TROPONIN AND TROPOMYOSIN (AIM 1), DEFINING THE EFFECTS OF R256H ON CARDIAC AND SKELETAL MUSCLE CELLS AND ENGINEERED TISSUES (AIM 2), AND ANALYZING THE EFFECTS OF R256H ON CARDIAC AND SKELETAL MUSCLES OF MICE (AIM 3). COMPLETING THESE AIMS WILL ESTABLISH THE ROLE OF SKELETAL MUSCLE ACTIN MUTATIONS IN DCM FOR THE FIRST TIME AND CREATE A MULTISCALE PLATFORM TO STUDY ADDITIONAL SKELETAL MUSCLE ACTIN MUTATIONS IN CARDIOMYOPATHY FOR THE PI'S FIRST R01. MOREOVER, WITH GUIDANCE OF A FORMAL MENTORING COMMITTEE, THE PI WILL COMPLETE A CURRICULUM THAT WILL BUILD HIS BIOCHEMISTRY AND BIOPHYSICS KNOWLEDGE AND TECHNIQUES, TEACH HIM CRYOEM STRUCTURAL ANALYSIS TO CONNECT STRUCTURE TO FUNCTION, AND EXPAND HIS UNDERSTANDING OF CARDIAC AND SKELETAL MUSCLE DISEASE MODELING IN ANIMALS. FINALLY, HE WILL IMPROVE HIS PROFESSIONAL, LOGISTICAL, AND EDUCATIONAL SKILLS TO FULLY TRANSITION TO AN INDEPENDENT INVESTIGATOR AND PRODUCTIVE MEMBER OF THE SCIENTIFIC COMMUNITY CAPABLE OF TRAINING FUTURE PHYSICIAN-SCIENTISTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $171.8k | 6/1/26 | ||
| Not listed | $171.8k | 6/30/25 | ||
| Not listed | $171.8k | 5/24/24 |